130 related articles for article (PubMed ID: 38850346)
1. Effectiveness and safety of secukinumab updosing in patients with moderate to severe plaque psoriasis: data from the PURE registry.
Papp KA; Gooderham M; Lynde C; Brassard D; Al-Mohammedi F; Prajapati VH; Delorme I; Albrecht L; Haydey R; Alam MS; Beecker J; Siddha S; Maguin M; Farag MS; Vieira A; Rihakova L; Langley RG
Arch Dermatol Res; 2024 Jun; 316(7):362. PubMed ID: 38850346
[TBL] [Abstract][Full Text] [Related]
2. Rationale, objectives and design of PURE, a prospective registry of patients with moderate to severe chronic plaque psoriasis in Canada and Latin America.
Papp KA; Gooderham M; Beecker J; Lynde CW; Delorme I; Dei-Cas I; Albrecht L; Rampakakis E; Sampalis JS; Vieira A; Hussein S; Chambenoit O; Rihakova L
BMC Dermatol; 2019 Jun; 19(1):9. PubMed ID: 31226985
[TBL] [Abstract][Full Text] [Related]
3. IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study.
Papp KA; Weinberg MA; Morris A; Reich K
Lancet; 2021 Apr; 397(10284):1564-1575. PubMed ID: 33894834
[TBL] [Abstract][Full Text] [Related]
4. Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial.
Augustin M; Reich K; Yamauchi P; Pinter A; Bagel J; Dahale S; You R; Bruin G; Djimopoulos J; Paguet B; Charef P; Patekar M; Keefe D
Br J Dermatol; 2022 Jun; 186(6):942-954. PubMed ID: 34981829
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.
Papp KA; Langley RG; Sigurgeirsson B; Abe M; Baker DR; Konno P; Haemmerle S; Thurston HJ; Papavassilis C; Richards HB
Br J Dermatol; 2013 Feb; 168(2):412-21. PubMed ID: 23106107
[TBL] [Abstract][Full Text] [Related]
6. Bimekizumab versus Secukinumab in Plaque Psoriasis.
Reich K; Warren RB; Lebwohl M; Gooderham M; Strober B; Langley RG; Paul C; De Cuyper D; Vanvoorden V; Madden C; Cioffi C; Peterson L; Blauvelt A
N Engl J Med; 2021 Jul; 385(2):142-152. PubMed ID: 33891380
[TBL] [Abstract][Full Text] [Related]
7. Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study.
Reich K; Puig L; Szepietowski JC; Paul C; Lacour JP; Tsianakas A; Sieder C; Rissler M; Pournara E; Orsenigo R
Br J Dermatol; 2020 Feb; 182(2):304-315. PubMed ID: 31102257
[TBL] [Abstract][Full Text] [Related]
8. Off-Label High-Dose Secukinumab for the Treatment of Moderate-to-Severe Psoriasis.
Phung M; Ighani A; Georgakopoulos JR; Vender R; Giroux L; Lansang P; Yeung J
J Cutan Med Surg; 2019; 23(4):391-393. PubMed ID: 30991818
[TBL] [Abstract][Full Text] [Related]
9. A prospective multicenter study assessing effectiveness and safety of secukinumab in a real-life setting in 158 patients.
Ortiz-Salvador JM; Saneleuterio-Temporal M; Magdaleno-Tapial J; Velasco-Pastor M; Pujol-Marco C; Sahuquillo-Torralba A; Mateu-Puchades A; Pitarch-Bort G; Marí-Ruiz JI; Mataix-Díaz J; Montesinos-Villaescusa E; Miralles-Botella J; García-Fernández L; Martorell-Calatayud A; Belinchón-Romero I; Sánchez-Carazo JL; Pérez-Ferriols A
J Am Acad Dermatol; 2019 Aug; 81(2):427-432. PubMed ID: 30872150
[TBL] [Abstract][Full Text] [Related]
10. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
Reich K; Armstrong AW; Langley RG; Flavin S; Randazzo B; Li S; Hsu MC; Branigan P; Blauvelt A
Lancet; 2019 Sep; 394(10201):831-839. PubMed ID: 31402114
[TBL] [Abstract][Full Text] [Related]
11. Secukinumab 2-weekly vs. 4-weekly dosing in patients with plaque-type psoriasis: results from the randomized GAIN study.
Reich K; Körber A; Mrowietz U; Sticherling M; Sieder C; Früh J; Bachhuber T
Br J Dermatol; 2021 May; 184(5):849-856. PubMed ID: 32652528
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Secukinumab Across Subgroups and Overall Safety in Pediatric Patients with Moderate to Severe Plaque Psoriasis: Week 52 Results from a Phase III Randomized Study.
Magnolo N; Kingo K; Laquer V; Browning J; Reich A; Szepietowski JC; Keefe D; Papanastasiou P; Bao W; Forrer P; Patekar M
Paediatr Drugs; 2022 Jul; 24(4):377-387. PubMed ID: 35698000
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of secukinumab in Taiwanese patients with moderate to severe plaque psoriasis: Subanalysis from ERASURE phase III study.
Wu NL; Hsu CJ; Sun FJ; Tsai TF
J Dermatol; 2017 Oct; 44(10):1129-1137. PubMed ID: 28493369
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and Safety of Secukinumab in Latin American Patients with Moderate to Severe Plaque Psoriasis: PURE Registry 12-Month Data.
Papp KA; Gooderham M; Dei-Cas I; LopezTello A; Garcia-Rodriguez JC; Taveras CY; Rousselin AH; Lavieri A; Maiolino M; Quintero DGV; Rihakova L; Salibe M; Pertuz W
Dermatol Ther (Heidelb); 2023 Jan; 13(1):269-283. PubMed ID: 36496547
[TBL] [Abstract][Full Text] [Related]
15. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011535. PubMed ID: 33871055
[TBL] [Abstract][Full Text] [Related]
16. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE).
Paul C; Lacour JP; Tedremets L; Kreutzer K; Jazayeri S; Adams S; Guindon C; You R; Papavassilis C;
J Eur Acad Dermatol Venereol; 2015 Jun; 29(6):1082-90. PubMed ID: 25243910
[TBL] [Abstract][Full Text] [Related]
17. Real-world data on the use of secukinumab as treatment for moderate-to-severe psoriasis in Chinese patients.
Huang H; Cai ML; Hong XJ; Zheng LJ; Hu ZL; Yuan T; Li WR; Sheng YJ; Zhang XJ
Eur J Dermatol; 2020 Oct; 30(5):554-560. PubMed ID: 33021475
[TBL] [Abstract][Full Text] [Related]
18. Bimekizumab versus Adalimumab in Plaque Psoriasis.
Warren RB; Blauvelt A; Bagel J; Papp KA; Yamauchi P; Armstrong A; Langley RG; Vanvoorden V; De Cuyper D; Cioffi C; Peterson L; Cross N; Reich K
N Engl J Med; 2021 Jul; 385(2):130-141. PubMed ID: 33891379
[TBL] [Abstract][Full Text] [Related]
19. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study.
Rich P; Sigurgeirsson B; Thaci D; Ortonne JP; Paul C; Schopf RE; Morita A; Roseau K; Harfst E; Guettner A; Machacek M; Papavassilis C
Br J Dermatol; 2013 Feb; 168(2):402-11. PubMed ID: 23362969
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J).
Saeki H; Nakagawa H; Nakajo K; Ishii T; Morisaki Y; Aoki T; Cameron GS; Osuntokun OO;
J Dermatol; 2017 Apr; 44(4):355-362. PubMed ID: 27726163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
